



# VIVOS INC.

Precision Radionuclide Therapy®

## **Vivos Inc. Reports Positive Independent Drug Elution Data Validating PrecisionGel™ for Sustained Localized Delivery**

Kennewick, Wash. — Vivos Inc. (“Vivos” or the “Company”) announced today the successful completion of independent third-party drug elution testing evaluating the controlled-release performance of the Company’s proprietary PLGA-g-PEG thermogelling hydrogel platform, a foundational component of its PrecisionGel™ technologies.

The testing was conducted by the PolySciTech Division of Akina, Inc. and evaluated the hydrogel platform’s ability to deliver sustained and localized release of therapeutic compounds over time — an important capability for precision oncology and localized therapeutic applications.

The study demonstrated that Vivos’ hydrogel formulations achieved controlled and sustained release profiles lasting up to 42 days, with the ability to tune release characteristics by modifying polymer composition and concentration.

“This testing represents another important step in validating the versatility and scientific foundation of our hydrogel technology platform,” said Dr. Michael Korenko. “Localized and sustained therapeutic delivery remains a major challenge across oncology and radionuclide therapies. These results support our belief that PrecisionGel™ and our broader PRnT platform may offer highly differentiated solutions capable of improving treatment precision while minimizing exposure to healthy tissue.”

Key findings from the independent evaluation included:

- Sustained therapeutic release profiles extending up to six weeks
- Stable and predictable release behavior across multiple formulations
- Ability to modify release speed through changes in polymer composition and concentration

- Evidence supporting customizable therapeutic delivery for varying clinical applications

The Company believes the independent third-party data provides additional scientific validation as Vivos continues advancing product development, manufacturing scale-up initiatives, and future regulatory activities related to its PrecisionGel™ and Precision Radionuclide Therapy™ pipeline. The full dataset will be submitted to a leading scientific peer-reviewed publication.

### **About Vivos Inc.**

[Vivos Inc.](#) is advancing next-generation Precision Radionuclide Therapy™ (PRnT) platforms designed to deliver highly targeted cancer treatment directly to tumors and surgical margins while minimizing exposure to surrounding healthy tissue. Through its proprietary technologies, RadioGel® for human applications and IsoPet® for veterinary oncology, Vivos is developing innovative minimally invasive therapies aimed at improving treatment precision, patient outcomes, and accessibility in both human and animal cancer care.

### **Forward-Looking Statements**

This press release contains forward-looking statements regarding future development, regulatory activities, commercialization opportunities, and potential therapeutic applications of Vivos' technologies. Actual results may differ materially from those projected due to various risks and uncertainties. Vivos undertakes no obligation to update forward-looking statements except as required by law.

### **Contact:**

Dr. Michael Korenko, C.E.O., Vivos Inc.

Brad Weeks, MBA, President, Vivos Inc.

[info@vivosinc.com](mailto:info@vivosinc.com)